Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion in vitro and reduces their metastatic potential in intrasplenic tumour mouse models...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeitany, Maya, Leroy, Cédric, Tosti, Priscillia, Lafitte, Marie, Le Guet, Jordy, Simon, Valérie, Bonenfant, Debora, Robert, Bruno, Grillet, Fanny, Mollevi, Caroline, El Messaoudi, Safia, Otandault, Amaëlle, Canterel‐Thouennon, Lucile, Busson, Muriel, Thierry, Alain R, Martineau, Pierre, Pannequin, Julie, Roche, Serge, Sirvent, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887546/
https://www.ncbi.nlm.nih.gov/pubmed/29438985
http://dx.doi.org/10.15252/emmm.201707918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887546/
https://www.ncbi.nlm.nih.gov/pubmed/29438985
http://dx.doi.org/10.15252/emmm.201707918

Ejemplares similares